Relyto 10 mg/ml (IV Infusion)
100 mg vial: ৳ 13,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Rituximab |
| Company | Incepta pharmaceuticals ltd |
Indications
- Non-Hodgkin's Lymphoma treatment
- Chronic Lymphocytic Leukemia treatment
- Rheumatoid Arthritis treatment
- Granulomatosis with Polyangiitis treatment
- Pemphigus Vulgaris treatment
- Treatment for different types of Non-Hodgkin's Lymphoma
- Maintenance therapy for certain lymphomas
Pharmacology
- Genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody
- Targeted against the CD20 antigen
- Approximate molecular weight of 145 kD
Dosage & Administration
- Intravenous administration only
- Specific infusion rates for different conditions
- Use in pediatric patients with mature B-cell NHL/B-AL
Interaction
- No formal drug interaction studies performed
- No alteration of systemic exposure to specific drugs
Contraindications
- Contraindicated in patients with known hypersensitivity to Rituximab
Side Effects
- Reactivation of hepatitis B virus
- Various infusion-related reactions
- Fever, rigors, pruritus, skin rashes
- Hypotension, flushing, asthenia, headache
- Hematological complications
Pregnancy & Lactation
- Potential fetal harm
- Adverse developmental outcomes
- Advice against breastfeeding during treatment and 6 months after last dose
Precautions & Warnings
- Severe, potentially fatal infusion-related reactions
- Severe mucocutaneous reactions
- Risk of Progressive Multifocal Leukoencephalopathy (PML)
- Tumor Lysis Syndrome (TLS) risk
- Risk of serious infections
Therapeutic Class
- Cytotoxic immunosuppressants
Storage Conditions
- Refrigeration at 2°C-8°C
- Protection from light
- Keep out of reach of children